S Chaudhari Diptaraj, Ghattargi Vikas, Shah Viqar, Gupta Saurabh, Bele Kedar, Pawar Shrikant
Mylab Discovery Solutions Private Limited, Pune, India.
Netsurf Communications Pvt. Ltd., Pune, India.
Bioinformation. 2023 Mar 31;19(3):278-283. doi: 10.6026/97320630019278. eCollection 2023.
The study estimates the usability and attitude assessment of users for India's first approved rapid antigen self-test kit; the CoviSelf™. India approved its first AI-powered self-test for Covid-19 in April 2021 a few weeks after the first approval in the US. We present here a study on usability and attitude assessment of users of India's first approved rapid antigen self-test kit; the CoviSelf™. The study evaluates participants' understanding of and performance of test procedure and interprets the results. Analysis revealed that more than 90% study participants followed steps correctly as illustrated in the user's manual. Age group and gender-based analysis showed comparable scores for usability of the test kit suggesting users of different age groups has same ease in using the test kit. What we learnt from this study could be start of self-test revolution, where rapid tests could expand the access of diagnostics for hundreds of diseases including HIV, HPV, and dengue to millions of people who could not get access to diagnostics because we lacked manpower or facility to conduct tests. Self-testing could break the barriers for diagnostics that Internet did for information.
该研究评估了印度首个获批的快速抗原自检试剂盒CoviSelf™的用户可用性和态度。印度于2021年4月批准了其首个用于新冠病毒的人工智能驱动的自检产品，这是在美国首次批准几周之后。我们在此展示一项关于印度首个获批的快速抗原自检试剂盒CoviSelf™用户可用性和态度评估的研究。该研究评估了参与者对检测程序的理解和操作情况，并对结果进行了解读。分析显示，超过90%的研究参与者按照用户手册中的说明正确地遵循了步骤。基于年龄组和性别的分析表明，该检测试剂盒的可用性得分相当，这表明不同年龄组的用户在使用该检测试剂盒时具有相同的便捷性。我们从这项研究中学到的可能是自检革命的开端，快速检测可以将包括艾滋病毒、人乳头瘤病毒和登革热在内的数百种疾病的诊断服务扩展到数百万无法获得诊断的人群，因为我们缺乏进行检测的人力或设施。自检可以打破诊断方面的障碍，就像互联网打破了信息方面的障碍一样。
